137 related articles for article (PubMed ID: 37858313)
1. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
Fukada I; Mori S; Hayashi N; Hosonaga M; Xiaofei W; Yamazaki M; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Ueno T; Takahashi S
Cancer Sci; 2023 Dec; 114(12):4632-4642. PubMed ID: 37858313
[TBL] [Abstract][Full Text] [Related]
2. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a cancer genomic profile test for patients with metastatic breast cancer.
Fukada I; Mori S; Hayashi N; Hosonaga M; Yamazaki M; Wang X; Kawai S; Inagaki L; Ozaki Y; Kobayashi K; Hara F; Kobayashi T; Ueki A; Osako T; Tonooka A; Takeuchi K; Ueno T; Takano T; Ohno S; Takahashi S
Sci Rep; 2022 Mar; 12(1):4813. PubMed ID: 35315838
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
[TBL] [Abstract][Full Text] [Related]
6. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
7. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
[TBL] [Abstract][Full Text] [Related]
8. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
9. Identification of barriers to implementation of precision oncology in patients with rare cancers.
Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
11. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.
Cifuentes C; Lombana M; Vargas H; Laguado P; Ruiz-Patiño A; Rojas L; Navarro U; Vargas C; Ricaurte L; Arrieta O; Zatarain-Barron L; Zapata L; González G; Ortiz C; Bernal L; Restrepo JG; Viola L; Grosso F; Zapata R; Mantilla W; Carranza H; Bustillo I; Llinas N; Duarte R; Rodríguez J; Archila P; Ávila J; Bermúdez M; Gámez T; Sotelo C; Otero J; Forero E; Lema M; Limpias C; Ordóñez-Reyes C; Mejía S; Rolfo C; Rosell R; Cardona AF; ;
Cancer Control; 2023; 30():10732748231175256. PubMed ID: 37148308
[TBL] [Abstract][Full Text] [Related]
12. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
13. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.
O'Haire S; Degeling K; Franchini F; Tran B; Luen SJ; Gaff C; Smith K; Fox S; Desai J; IJzerman M
Target Oncol; 2022 Sep; 17(5):539-548. PubMed ID: 36063280
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
17. An approach for improvement of the accuracy of cancer gene panel testing.
Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
19. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
20. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
Matsuo M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
In Vivo; 2023; 37(5):2147-2154. PubMed ID: 37652518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
